Histogen
Financials
Estimates*
| USD | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Revenues | 11.3m | 2.1m | <1m | 3.8m |
| % growth | - | (82 %) | (55 %) | 310 % |
| EBITDA | 1.1m | (4.6m) | (15.4m) | (10.6m) |
| % EBITDA margin | 9 % | (222 %) | (1681 %) | (282 %) |
| Profit | (3.0m) | (18.8m) | (14.9m) | (10.6m) |
| % profit margin | (26 %) | (912 %) | (1627 %) | (282 %) |
| EV / revenue | - | 4.9x | 2.9x | -1.0x |
| EV / EBITDA | - | -2.2x | -0.2x | 0.4x |
| R&D budget | 4.1m | 6.2m | 8.5m | 5.0m |
| R&D % of revenue | 36 % | 302 % | 922 % | 133 % |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$5.4m | Series A | ||
$10.0m | Series A | ||
| N/A | N/A | Series B | |
$24.9m | Late VC | ||
$6.0m | Series D | ||
* | $750k | Grant | |
| N/A | N/A | IPO | |
$2.0m | Grant | ||
* | N/A | $3.5m | Private Placement VC |
| Total Funding | $52.6m | ||
Related Content
Recent News about Histogen
EditHistogen Inc. is a biotechnology company specializing in regenerative medicine, focusing on developing and commercializing products that stimulate the body's own stem cells to regenerate tissues. The company primarily serves clients in the hair growth, skincare, and orthopedic markets. Histogen operates in the biotechnology sector, leveraging its proprietary technology platform to create products that address unmet medical needs. The business model revolves around research and development, clinical trials, and subsequent commercialization of its products. Revenue is generated through product sales, licensing agreements, and partnerships with other companies in the healthcare sector. Histogen's key products include HST 001 for hair growth, HST 002 for skincare, and HST 003 for orthopedic applications. The company aims to provide innovative solutions that improve patient outcomes and quality of life.
Keywords: regenerative medicine, biotechnology, hair growth, skincare, orthopedic, stem cells, clinical trials, product commercialization, healthcare partnerships, innovative solutions.